Country: EU
Laboratories❯
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
The site is temporarily down due to maintenance. Sorry for the inconvenience.
Quality & Accuracy
Experience
The latest technologies
Speed &
Credibility
₾195.00
Study material: Venous blood
Response time (working day): 14
The test is done on an empty stomach: Yes
Home call service: YesRoma Index (Ovarian Malignancy Risk Algorithm)
The Roma index is a reliable test for the differentiation of ovarian epithelial tumors and benign formations. It is not a stand-alone screening test for ovarian cancer. It is used to assess the risk of ovarian malignancy in the presence of bulky appendages.
The Roma Index, or ovarian malignancy risk assessment algorithm, combines carcinoembryonic antigen Ca-125 and human epididymal (seminal epididymal) protein 4 and assesses menopausal status and risk of ovarian malignancy in women with small pelvic masses.
Roma index can be determined: for people over 18 years of age, with bulky processes of small pelvis and ovarian appendages, when planning operative treatment. ROMA-index data are not considered independently, but in the context of clinical and radiological data.
The study is conducted only on women
Warning
Evaluation of the ROMA-index without clinical-radiological data is incorrect. Also, it is not an indicator for determining the need for surgical treatment.
A low rate of Roma in the initial stage does not exclude consultation with an oncologist and observation of the dynamics.
Roma-Index is not used: in women who have previously been treated for cancer, during a course of chemotherapy, in pregnant women, in young people under the age of 18.
During volumetric processes of the small pelvis, for differential diagnostics
Ovarian carcinoma antigen CA125 <35
Human epididymal protein HE4: in premenopause: < 70; in postmenopause: < 140;
Interpretation of ROMA-index data
In premenopause:
< 7,4 low risk
< 25,3 high risk
in postmenopause
> 7,4 high risk
> 25,3 low risk
Research method: electrochemiluminescent immunoassay
Research material: blood serum
Preparation of the patient for the study: Patients taking high doses of biotin-containing drugs (>5 mg/day) should refrain from taking the drug for at least 8 hours after taking the material.
Other tests
Testing process
 |
 |
|
Purchase a test |
Submission of material |
 |
 |
|
Results Online |
Consult a doctor |
More than 1000 routine and complex/specific diagnostic tests in all major areas of clinical pathology.
48 laboratory centers in 25 cities of Georgia: Tbilisi, Rustavi, Kutaisi, Batumi, Marneuli, Telavi, Zugdidi, Zestafon, Gori, Kobuleti, Akhaltsikhe, Khashuri, Sartichala, Kazbegi, Borjomi, Samtredia, Gurjaani, Lagodekhi, Akhmeta, Ozurgeti, Poti, Chiatura , Dusheti, Kareli, New Gudauri.
Use the Synevo web platform to view results from anywhere and anytime
Use the Synevo web platform to view results from anywhere, anytime
From Monday to Saturday you can use the laboratory services at home.
☎️ Hotline: 239 38 33 or 239 40 65
577293008 (9:00-დან 17:00-მდე)
30 laboratory centers in 11 cities of Georgia: Tbilisi, Kutaisi, Batumi, Kobuleti, Zugdidi, Zestaponi, Rustavi, Marneuli, Akhaltsikhe, Telavi, Gori.
More than 3000 routine and complex / specific diagnostic tests in all major areas of clinical pathology.
"Synevo" - Providing a wide range of diagnostic services in Georgia, offering more than 1,000 routine and specific diagnostic tests in all major areas of clinical pathology. By the end of 2023, the Synevo Georgia network will include 3 clinical laboratories and 47 blood sampling units, which will perform more than 300,000 tests.
Contact information
Address: Tsinandali St. N9 (N1 Clinical Hospital area)
2021 – 2023 © Synevo. all rights reserved
